ABSTRACT
Introducción Los tumores malignos del tracto urinario están asociados a gran morbimortalidad siendo su prevalencia variable a nivel global. Recientemente el estudio IDENTIFY ha publicado resultados sobre la prevalencia del cáncer del tracto urinario a nivel internacional. Este estudio evalúa la prevalencia de cáncer dentro de la cohorte española del estudio IDENTIFY para determinar si los resultados publicados son extrapolables a nuestra población. Material y métodos Se realizó un análisis de los datos de la cohorte de pacientes españoles del estudio IDENTIFY. Se trata de una cohorte prospectiva de pacientes derivados al hospital con sospecha de cáncer, predominantemente por hematuria. Los pacientes fueron reclutados entre diciembre de 2017 y diciembre de 2018. Resultados En total 706 pacientes procedente de 9 centros españoles fueron analizados. Doscientos setenta y siete pacientes (39,2%) fueron diagnosticados de cáncer, 259 (36,7%) de cáncer vejiga, 10 (1,4%) de tracto urinario superior, 9 (1,2%) renal y 5 (0,7%) de próstata. El aumento de la edad (OR: 1,05; IC 95%: 1,03-1,06; p<0,001), presencia de hematuria visible (OR: 2,19; IC 95%: 1,13-4,24; p=0,02) y el hábito tabáquico (exfumadores: OR: 2,11; IC 95%: 1,30-3,40; p=0,002; fumadores: OR: 2,36; IC 95%: 1,40-3,95; p=0,001) se asocia con mayor probabilidad de cáncer vesical. Conclusión Este estudio resalta el riesgo que existe en pacientes con HV y hábito tabáquico de presentar cáncer de vejiga. El cáncer de vejiga presentó la mayor prevalencia, siendo esta mayor que la expuesta en series previas y la presentada en el estudio IDENTIFY. Trabajos futuros deben evaluar otros factores asociados que permitan crear modelos de predicción de cáncer para seguir aumentando la detección de estos en nuestros pacientes. (AU)
Introduction Malignant tumors of the urinary tract are associated with high morbidity and mortality, and their prevalence can vary worldwide. Recently, the IDENTIFY study has published results on the prevalence of urinary tract cancer at a global level. This study evaluates the prevalence of cancer within the Spanish cohort of the IDENTIFY study to determine whether the published results can be extrapolated to our population. Patients and methods An analysis of the data from the Spanish cohort of patients in the IDENTIFY study was performed. This is a prospective cohort of patients referred to secondary care with suspected cancer, predominantly due to hematuria. Patients were recruited between December 2017 and December 2018. Results A total of 706 patients from 9 Spanish centers were analyzed. Of these, 277 (39.2%) were diagnosed with cancer: 259 (36.7%) bladder cancer, 10 (1.4%) upper tract urothelial carcinoma, 9 (1.2%) renal cancer and 5 (0.7%) prostate cancer. Increasing age (OR: 1.05; 95% CI: 1.03-1.06; P<.001), visible hematuria (VH) OR: 2.19; 95% CI: 1.13-4.24; P=.02)and smoking (ex-smokers: OR: 2.11; 95% CI: 1.30-3.40; P=.002); (smokers: OR: 2.36; 95% CI: 1.40-3.95; P=.001) were associated with higher probability of bladder cancer. Conclusion This study highlights the risk of bladder cancer in patients with VH and smoking habits. Bladder cancer presented the highest prevalence; higher than the prevalence reported in previous series and presented in the IDENTIFY study. Future work should evaluate other associated factors that allow us to create cancer prediction models to improve the detection of cancer in our patients. (AU)
Subject(s)
Humans , Male , Female , Adolescent , Young Adult , Adult , Middle Aged , Aged , Aged, 80 and over , Carcinoma, Transitional Cell , Urinary Bladder Neoplasms , Kidney Neoplasms , Prevalence , Risk Factors , Spain , Cohort Studies , Prospective StudiesABSTRACT
INTRODUCTION: Renal trauma is the most common of urological trauma and accounts for up to 5% of all. The AAST scale is the most widely used to assess renal trauma. This study focuses on high-grade trauma, whose treatment has evolved towards a conservative approach, with techniques such as angioembolization. The aim is to describe the evolution in the management of high-grade renal trauma in all patients treated at La Paz University Hospital from 2001 to 2022. METHODS: A descriptive retrospective study was conducted on patients treated at the hospital. The study was divided into two periods (2001-2010 and 2011-2022). A total of 285 patients with renal trauma were collected, of which 54 were high grade. The main variable is the type of management, conservative (embolization) or interventional through nephrectomy. RESULTS: In the completed series, there was a decrease in radical nephrectomy in high-grade renal trauma from 50% to 13.8% over time, with an increase in embolization from 23,1% to 44,8%. In patients with isolated renal trauma, those treated with embolization increased from 28.6% to 69.2%, while those undergoing radical/partial nephrectomy decreased from 42.8% to 7.69%. CONCLUSION: The management of renal trauma has evolved over the years in our center. The number of patients treated by embolization has increased, while the number of complications and nephrectomies has decreased.
ABSTRACT
INTRODUCTION: Malignant tumors of the urinary tract are associated with high morbidity and mortality, and their prevalence can vary worldwide. Recently, the IDENTIFY study has published results on the prevalence of urinary tract cancer at a global level. This study evaluates the prevalence of cancer within the Spanish cohort of the IDENTIFY study to determine whether the published results can be extrapolated to our population. PATIENTS AND METHODS: An analysis of the data from the Spanish cohort of patients in the IDENTIFY study was performed. This is a prospective cohort of patients referred to secondary care with suspected cancer, predominantly due to hematuria. Patients were recruited between December 2017 and December 2018. RESULTS: A total of 706 patients from 9 Spanish centers were analyzed. Of these, 277 (39.2%) were diagnosed with cancer: 259 (36.7%) bladder cancer, 10 (1.4%) upper tract urothelial carcinoma, 9 (1.2%) renal cancer and 5 (0.7%) prostate cancer. Increasing age (OR 1.05 (95% CI 1.03-1.06; Pâ¯<â¯0.001)), visible hematuria (VH) OR 2.19 (95% CI 1.13-4.24; Pâ¯=â¯0.02)) and smoking (ex-smokers: OR 2.11(95% CI 1.30-3.40; Pâ¯=â¯0.002); smokers: OR 2.36 (95% CI 1.40-3.95; Pâ¯=â¯0.001)) were associated with higher probability of bladder cancer. CONCLUSION: This study highlights the risk of bladder cancer in patients with VH and smoking habits. Bladder cancer presented the highest prevalence; higher than the prevalence reported in previous series and presented in the IDENTIFY study. Future work should evaluate other associated factors that allow us to create cancer prediction models to improve the detection of cancer in our patients.
Subject(s)
Carcinoma, Transitional Cell , Urinary Bladder Neoplasms , Urologic Neoplasms , Male , Humans , Urinary Bladder Neoplasms/complications , Carcinoma, Transitional Cell/pathology , Hematuria/epidemiology , Hematuria/etiology , Prospective Studies , Prevalence , Urologic Neoplasms/epidemiologyABSTRACT
INTRODUCTION: The improved image resolution of IMAGE1 S technology will increase tumor detection, achieve a greater number of complete resections, and would probably have an impact on the reduction of recurrences. AIM: The primary objective was to compare the recurrence rates of IMAGE1 S vs. white light during transurethral resection of the bladder (TUR); the secondary objective was to compare the complication rates according to Clavien-Dindo (CD) at 12 months of follow-up. METHODS: Prospective, randomized 1:1, blinded clinical trial. Recurrence and complication rates according to CD were analyzed using chi-square/U Mann-Whitney tests and recurrence-free survival (RFS) using Kaplan-Meier curves. The European Association of Urology (EAU) 2021 scoring model was used. RESULTS: The analysis included 103 participants; 49 were assigned to the IMAGE1 S group and 54 to the white light group. Recurrence rates were 12.2% and 25.9%, respectively (Pâ¯=â¯.080). The low and intermediate risk group had a lower recurrence rate with IMAGE1 S (7.7% vs. 30.8%, Pâ¯=â¯.003) and a higher RFS with IMAGE1 S (85.2% vs. 62.8% Log Rank: 0.021), with a Hazard Ratio of 0.215 (95% CI: 0.046-0.925). No differences were observed in the high and very high-risk groups. Complications were mostly grade I and rates were similar between both groups (IMAGE1 S 20.4% vs. white light 7.4% Pâ¯=â¯.083). CONCLUSIONS: There were no differences in the recurrence rates between groups. However, the low and intermediate risk group had a lower recurrence rate with IMAGE1 S. In addition, perioperative complication rates were not higher.
ABSTRACT
PURPOSE OF REVIEW: Pathologies of the prostate in men are one of the most prevalent clinical conditions today [1]. Specifically, pelvic inflammatory disease such as prostatitis can cause symptoms and syndromes different from urological ones, such as bowel or nervous system manifestations. This has a largely negative impact on the quality of life of patients. Therefore, it is convenient to know and update the information about the therapeutic approach to prostatitis, which is a challenge that involves different medical specialties. The aim of this article is to provide summarized and focused evidence to help in the therapeutic approach of patients with prostatitis. A computer-based search of the PubMed and Cochrane Library databases was used to perform a comprehensive literature review on prostatitis, with special interest in recent findings and latest therapeutic guideline recommendations. RECENT FINDINGS: Recent discoveries about the epidemiology and clinical classifications of prostatitis seem to incur in an increasingly individualized and directed management, with the aim of covering all the confluent factors in prostatic inflammatory pathology. In addition, the role of new drugs and combination with phytotherapy open up a range of new treatment possibilities, although future randomized studies will be necessary to better understand how to use all treatment modalities. Despite all the knowledge acquired about the pathophysiology of prostate diseases, and due to their interrelation with other pelvic systems and organs, there are still gaps that make it difficult for us to provide an optimal and standardized treatment in many of our patients. Being aware of the influence of all the factors potentially involved in prostate symptoms is crucial for a correct diagnosis and establishing an effective treatment plan.
Subject(s)
Prostatitis , Male , Humans , Chronic Disease , Prostatitis/diagnosis , Quality of Life , Pelvic Pain/therapy , Phytotherapy/adverse effectsSubject(s)
Humans , Male , Clinical Decision-Making , Prostatic Neoplasms , Biomarkers, Tumor , Neoplasm Staging , PrognosisSubject(s)
Prostatic Neoplasms , Decision Making , Humans , Male , Prognosis , Prostatic Neoplasms/genetics , Prostatic Neoplasms/therapyABSTRACT
Introducción La práctica en modelos experimentales es una opción válida que mejora los resultados y acorta las curvas de aprendizaje de las técnicas quirúrgicas.Nuestro objetivo fue desarrollar un modelo en plástico, impreso en 3D para la docencia, el entrenamiento y la formación en ureteroscopia flexible, analizando costes e idoneidad para la práctica de esta técnica quirúrgica.Métodos Se elaboró un modelo impreso en 3D a partir de una tomografía axial computarizada de una vía urinaria superior de un paciente real. La segmentación se llevó a cabo mediante el software HorosTM y la impresión mediante una impresora FDM-Ultimaker.Se numeró los cálices renales para ser identificados, como en el plan de formación de tratamiento endoscópico de litiasis, ejercicio 4, de la Asociación Europea de Urología.Se utilizaron: un ureteroscopio flexible desechable Innovex (Palex) y cestillas de nitinol (Coloplast).Resultados El tiempo de impresión fue de 19h, con un coste total de 8,77.El modelo tridimensional permitió la introducción del ureteroscopio flexible y la exploración de los cálices renales por parte de urólogos tanto en formación como en ejercicio actual de la especialidad sin dificultad.El modelo también permitió la utilización de cestillas y la movilización y extracción de litiasis previamente colocadas.Conclusión Damos a conocer un modelo tridimensional válido para ejercicios de formación en ureteroscopia flexible con unos costes razonables, que permitirá adquirir la destreza y la confianza necesaria para iniciar el procedimiento en un escenario real (AU)
Introduction Training in experimental models is a valid option that improves the outcomes and shortens surgical learning curves.Our objective was to develop a 3D printed plastic model for teaching, training and education in flexible ureteroscopy, analyzing costs and suitability for the practice of this surgical technique.Methods A 3D printed model was developed based on a CT scan from a real-life patient's upper urinary tract. HorosTM software was used for segmentation and an FDM-Ultimaker for 3D printing.Renal calyces were numbered to be identified, as in the European Association of Urology Endoscopic Stone Treatment training curriculum, Task 4.The following were used: Innovex single-use flexible ureteroscope (Palex) and nitinol baskets (Coloplast).Results Printing time was 19hours, with a total cost of 8.77.The three-dimensional model allowed the insertion of the flexible ureteroscope and the exploration of the renal calyces by urologists in training as well as in current practice of the specialty without difficulty.The model also allowed the use of baskets and the mobilization and removal of previously placed stones.Conclusion We unveil a valid three-dimensional model for flexible ureteroscopy training exercises with reasonable costs, which will allow acquiring the necessary skills and confidence to initiate the procedure in a real-life scenario (AU)
Subject(s)
Humans , Printing, Three-Dimensional , Ureteroscopy/education , Simulation Training/economicsABSTRACT
INTRODUCTION: Training in experimental models is a valid option that improves the outcomes and shortens surgical learning curves. Our objective was to develop a 3D printed plastic model for teaching, training and education in flexible ureteroscopy, analyzing costs and suitability for the practice of this surgical technique. METHODS: A 3D printed model was developed based on a CT scan from a real-life patient's upper urinary tract. Horos™ software was used for segmentation and an FDM-Ultimaker for 3D printing. Renal calyces were numbered to be identified, as in the European Association of Urology Endoscopic Stone Treatment training curriculum, Task 4. The following were used: Innovex single-use flexible ureteroscope (Palex) and nitinol baskets (Coloplast). RESULTS: Printing time was 19â¯h, with a total cost of 8.77. The three-dimensional model allowed the insertion of the flexible ureteroscope and the exploration of the renal calyces by urologists in training as well as in current practice of the specialty without difficulty. The model also allowed the use of baskets and the mobilization and removal of previously placed stones. CONCLUSION: We unveil a valid three-dimensional model for flexible ureteroscopy training exercises with reasonable costs, which will allow acquiring the necessary skills and confidence to initiate the procedure in a real-life scenario.
Subject(s)
Ureteroscopes , Urology , Humans , Printing, Three-Dimensional , Ureteroscopy , UrologistsABSTRACT
Introducción: Las recidivas del carcinoma urotelial (CaU) en uretra o en el tracto urinario superior (TUS), tras una cistectomía radical (CR) son infrecuentes (4-6%), y su diagnóstico suele ocurrir en los 2 primeros años. Actualmente, no existen claras recomendaciones para la detección de recidivas en el urotelio remanente (UR), aunque se sabe que su detección precoz ofrece beneficios en la supervivencia. Nuestro objetivo es determinar el valor diagnóstico de la citología urinaria (CU) para la detección de recidivas en el UR y calcular su impacto como método de diagnóstico precoz en la supervivencia.Material y métodosRevisión retrospectiva de pacientes intervenidos de CR por CaU entre 2008-2016, con un seguimiento mayor de 24 meses.ResultadosSe incluyeron 142 pacientes. En una mediana de seguimiento de 68,5 meses, 9 pacientes (6,3%) presentaron recidivas en el UR (uretra: 4, TUS: 4, sincrónica: uno). La sensibilidad de la CU para el diagnóstico de recidivas en el TUS fue del 20% y la especificidad del 96%. No se encontraron diferencias significativas entre la supervivencia global y la supervivencia cáncer específica entre pacientes según el resultado de la CU.ConclusiónLas recidivas en el UR tras una CR son infrecuentes, y en nuestro estudio, hemos encontrado una baja sensibilidad para el diagnóstico de estas con CU. Por estas razones, no consideramos que la CU aporta información útil para el seguimiento de estos pacientes. (AU)
Introduction: Urethral or upper urinary tract (UUT) recurrence of urothelial carcinoma (UC) after radical cystectomy (RC) are rare (4-6%), and their diagnosis usually occurs within the first two years. Although it is known that its early detection offers benefit in terms of survival, currently there are no clear recommendations for the detection of recurrence in the remnant urothelium (RU). Our aim is to determine the diagnostic value of urinary cytology for the detection of recurrences in the RU and to estimate its impact as an early diagnostic method on survival.Material and methodsRetrospective review of patients who underwent RC for urothelial carcinoma between 2008-2016, with a follow-up of at least 24 months.ResultsThe study included 142 patients. In a median follow-up of 68.5 months, nine patients (6.3%) presented recurrences in the RU (urethra: four, UUT: four, synchronous: one). The sensitivity and specificity of urinary cytology for the diagnosis of UUT recurrences were 20% and 96%, respectively. No significant differences were found between overall survival and cancer-specific survival among patients according to the urinary cytology results.ConclusionRecurrences in the RU after RC are infrequent; our study has shown that urinary cytology offers a low sensitivity for their diagnoses. For these reasons, we do not consider that urinary cytology provides useful information for surveillance of these patients. (AU)
Subject(s)
Humans , Carcinoma, Transitional Cell/diagnosis , Cystectomy , Prognosis , Urinary Bladder Neoplasms/diagnosis , Retrospective StudiesABSTRACT
INTRODUCTION: Urethral or upper urinary tract (UUT) recurrence of urothelial carcinoma (UC) after radical cystectomy (RC) are rare (4-6%), and their diagnosis usually occurs within the first two years. Although it is known that its early detection offers benefit in terms of survival, currently there are no clear recommendations for the detection of recurrence in the remnant urothelium (RU). Our aim is to determine the diagnostic value of urinary cytology for the detection of recurrences in the RU and to estimate its impact as an early diagnostic method on survival. MATERIAL AND METHODS: Retrospective review of patients who underwent RC for urothelial carcinoma between 2008-2016, with a follow-up of at least 24 months. RESULTS: The study included 142 patients. In a median follow-up of 68.5 months, nine patients (6.3%) presented recurrences in the RU (urethra: four, UUT: four, synchronous: one). The sensitivity and specificity of urinary cytology for the diagnosis of UUT recurrences were 20% and 96%, respectively. No significant differences were found between overall survival and cancer-specific survival among patients according to the urinary cytology results. CONCLUSION: Recurrences in the RU after RC are infrequent; our study has shown that urinary cytology offers a low sensitivity for their diagnoses. For these reasons, we do not consider that urinary cytology provides useful information for surveillance of these patients.
Subject(s)
Carcinoma, Transitional Cell , Urinary Bladder Neoplasms , Carcinoma, Transitional Cell/diagnosis , Cystectomy , Humans , Male , Neoplasm Recurrence, Local/diagnosis , Prognosis , Retrospective Studies , Urethra , Urinary Bladder Neoplasms/diagnosisABSTRACT
Introducción: En los últimos años, la vigilancia activa (VA) ha ganado popularidad como una opción segura y razonable para los pacientes con cáncer de próstata de bajo riesgo clínicamente localizado.ObjetivoResumir la información más reciente sobre el uso de resonancia magnética multiparamétrica (RMmp) en el contexto de la vigilancia activa (VA) para el tratamiento del cáncer de próstata (CaP).Adquisición de la evidenciaSe realizó una búsqueda en la literatura en inglés mediante PubMed hasta febrero de 2020. Se seleccionaron los artículos originales, metaanálisis, y revisiones sistemáticas más relevantes.Síntesis de la evidenciaLa gran importancia de la RMmp de la próstata en el contexto del diagnóstico del CaP es su capacidad de detectar lesiones cancerosas de alto grado que pueden haber sido omitidas en biopsias sistemáticas. Diversos estudios han demostrado que la RMmp tiene un rendimiento superior con respecto a los modelos basados en la clínica para identificar aquellos candidatos que se beneficiarán más de la VA. Aunque hay poca información sobre la RMmp de próstata durante el seguimiento de hombres en VA, existe la posibilidad de que ésta pueda mejorar significativamente los programas de VA, gracias a una selección más rigurosa de candidatos óptimos, una identificación más precisa de la progresión de la enfermedad, y una reducción en el número de biopsias. El objetivo de la reevaluación de los pacientes sometidos a VA es encontrar el momento en el que cambiar la estrategia hacia el tratamiento activo sea lo más efectivo.ConclusiónEl valor de la RMmp ha sido reconocido debido a su alto valor predictivo negativo (VPN) en la detección de lesiones de mayor grado en pacientes con CaP de bajo riesgo. Un mejor sistema de detección en las pruebas de imagen y un diagnóstico más exacto con RMmp podría reducir las clasificaciones erróneas en el diagnóstico inicial y durante el seguimiento, reduciendo así el número de biopsias. (AU)
Introduction: In recent years, active surveillance (AS) has gained popularity as a safe and reasonable option for patients with low-risk, clinically localized prostate cancer.ObjectiveTo summarize the latest information regarding the use of mpMRI in the setting of active surveillance (AS) for the management of prostate cancer (PCa).Evidence acquisitionA PubMed-based, English literature search was conducted through February 2020. We selected the most relevant original articles, meta-analyses and systematic reviews that could provide important information.Evidence synthesisThe great importance of mpMRI of the prostate in the setting of PCa diagnosis is its ability to visualize primarily high-grade cancerous lesions potentially missed on systematic biopsies. In several studies, mpMRI has shown an improved performance over clinically based models for identifying candidates which will benefit the most from AS. Although data on prostate mpMRI during follow-up of men under AS is sparse, it holds the probability to improve significantly AS programs by a more precise selection of optimal candidates, a more accurate identification of disease progression and a reduction in number of biopsies. The goal of reassessment of patients undergoing AS is to find the most effective moment to change attitude to active treatment.ConclusionThe value of mpMRI has been recognized due to its high negative predictive value (NPV) for lesion upgrading in low-risk PCa patients. The improvement in imaging detection, and precise diagnosis with mpMRI could reduce misclassifications at initial diagnosis and during follow-up, reducing the number of biopsies. (AU)
Subject(s)
Humans , Magnetic Resonance Spectroscopy , Patients , Prostatic Neoplasms/diagnostic imaging , Prostatic Neoplasms/therapy , Watchful Waiting , Follow-Up StudiesABSTRACT
A 66-year-old male patient in follow-up in the urology department for a non-muscle-invasive bladder cancer was detected by ultrasound to have absence of the left kidney and a cystic, multilobed image at the location of the seminal vesicle. Magnetic resonance imaging reveals left renal agenesis and the existence of multiple cysts in the ipsilateral seminal vesicle that reaches a size of 6.9 × 3.7 cm, as well as a ureteral remnant that opens into the seminal vesicle. The patient does not present urinary symptoms, neither pain with ejaculation nor hematuria. A triad of seminal vesicle cyst, ipsilateral renal agenesis, and ipsilateral ejaculatory duct obstruction is known as Zinner syndrome. Congenital anomalies of the seminal vesicles are rare; some of them are associated with malformations of the upper urinary system. Seminal vesicle cysts are associated with ipsilateral renal agenesis and ectopic or dysplastic ureter. Patients may remain asymptomatic and be diagnosed incidentally or may present with symptoms such as increased urinary frequency, dysuria, recurrent infections, pain with ejaculation, and perineal discomfort.
ABSTRACT
INTRODUCTION: In recent years, active surveillance (AS) has gained popularity as a safe and reasonable option for patients with low-risk, clinically localized prostate cancer. OBJECTIVE: To summarize the latest information regarding the use of mpMRI in the setting of active surveillance (AS) for the management of prostate cancer (PCa). EVIDENCE ACQUISITION: A PubMed-based, English literature search was conducted through February 2020. We selected the most relevant original articles, meta-analyses and systematic reviews that could provide important information. EVIDENCE SYNTHESIS: The great importance of mpMRI of the prostate in the setting of PCa diagnosis is its ability to visualize primarily high-grade cancerous lesions potentially missed on systematic biopsies. In several studies, mpMRI has shown an improved performance over clinically based models for identifying candidates which will benefit the most from AS. Although data on prostate mpMRI during follow-up of men under AS is sparse, it holds the probability to improve significantly AS programs by a more precise selection of optimal candidates, a more accurate identification of disease progression and a reduction in number of biopsies. The goal of reassessment of patients undergoing AS is to find the most effective moment to change attitude to active treatment. CONCLUSION: The value of mpMRI has been recognized due to its high negative predictive value (NPV) for lesion upgrading in low-risk PCa patients. The improvement in imaging detection, and precise diagnosis with mpMRI could reduce misclassifications at initial diagnosis and during follow-up, reducing the number of biopsies.
Subject(s)
Multiparametric Magnetic Resonance Imaging , Patient Selection , Prostatic Neoplasms/diagnostic imaging , Prostatic Neoplasms/therapy , Watchful Waiting , Follow-Up Studies , Humans , MaleABSTRACT
No disponible
Subject(s)
Animals , Blood Vessels , Intraoperative Complications/surgery , Laparoscopy/education , Urologic Surgical Procedures , Disease Models, Animal , Swine , Vascular Surgical ProceduresABSTRACT
INTRODUCCIÓN: El curso clínico del cáncer de próstata (CaP) es marcadamente diverso, desde enfermedad indolente a enfermedad altamente agresiva y diseminada. Las técnicas de imagen molecular están desempeñando cada vez un papel más importante en la detección temprana de CaP, estadificación y en la detección de recurrencia. Existen algunas modalidades de imagen molecular y agentes radiotrazadores, cuyo rendimiento es importante en la práctica clínica actual de CaP. OBJETIVO: Esta revisión resume la información más reciente sobre técnicas de imagen molecular de CaP, y está diseñada para asistir a los urólogos en la petición e interpretación de estas modalidades y radiotrazadores para uso en diferentes pacientes. ADQUISICIÓN DE EVIDENCIA: Se realizó una búsqueda bibliográfica en PubMed hasta septiembre de 2019. Seleccionamos los artículos originales, metaanálisis y revisiones bibliográficas más recientes y relevantes que han proporcionado información del uso de modalidades de imagen molecular y de radiotrazadores en CaP. SÍNTESIS DE EVIDENCIA: En esta revisión discutimos 3 de las principales modalidades de imagen molecular y 7 tecnologías de radiotrazadores disponibles. CONCLUSIONES: El uso de las modalidades de imagen molecular y radiotrazadores tiene un papel importante en la recurrencia bioquímica y el diagnóstico de la progresión ósea y ganglionar de CaP. En la actualidad, ninguna de estas modalidades de imagen molecular se puede recomendar sobre la valoración clásica con tomografía computarizada abdominopélvica y gammagrafía ósea, y se requieren estudios multiinstitucionales y a gran escala para validar la eficacia y el coste-utilidad de estas nuevas tecnologías
INTRODUCTION: The clinical course of Prostate cancer (PCa) are markedly diverse, ranging from indolent to highly aggressive disseminated disease. Molecular imaging techniques are playing an increasing role in early PCa detection, staging and disease recurrence. There are some molecular imaging modalities, radiotracers agents and its performance are important in current clinical practice PCa. OBJECTIVE: This review summarizes the latest information regarding molecular imaging of PCa and is designed to assist urologists with ordering and interpreting these modalities and different radiotracers for different patients. EVIDENCE ACQUISITION: A PubMed-based literature search was conducted up to September 2019. We selected the most recent and relevant original articles, metanalysis and reviews that have provided relevant information to guide molecular imaging modalities and radiotracers use. EVIDENCE SYNTHESIS: In this review, we discuss 3 main molecular imaging modalities and 7 radiotracer technologies available. CONCLUSIONS: The use molecular imaging modalities and radiotracers has a unique role in biochemical recurrence and diagnosis of ganglionar and bone progression of PCa. In the present time, no one of these molecular imaging modalities can be recommended over the classical work-up of abdominopelvic CT scan and bone scan, and large-scale and multi-institutional studies are required to validate the efficacy and cost utility of these new technologies
Subject(s)
Humans , Male , Molecular Imaging/methods , Prostatic Neoplasms/diagnostic imaging , RadiopharmaceuticalsABSTRACT
INTRODUCTION: The clinical course of Prostate cancer (PCa) are markedly diverse, ranging from indolent to highly aggressive disseminated disease. Molecular imaging techniques are playing an increasing role in early PCa detection, staging and disease recurrence. There are some molecular imaging modalities, radiotracers agents and its performance are important in current clinical practice PCa. OBJECTIVE: This review summarizes the latest information regarding molecular imaging of PCa and is designed to assist urologists with ordering and interpreting these modalities and different radiotracers for different patients. EVIDENCE ACQUISITION: A PubMed-based literature search was conducted up to September 2019. We selected the most recent and relevant original articles, metanalysis and reviews that have provided relevant information to guide molecular imaging modalities and radiotracers use. EVIDENCE SYNTHESIS: In this review, we discuss 3 main molecular imaging modalities and 7 radiotracer technologies available. CONCLUSIONS: The use molecular imaging modalities and radiotracers has a unique role in biochemical recurrence and diagnosis of ganglionar and bone progression of PCa. In the present time, no one of these molecular imaging modalities can be recommended over the classical work-up of abdominopelvic CT scan and bone scan, and large-scale and multi-institutional studies are required to validate the efficacy and cost utility of these new technologies.
Subject(s)
Molecular Imaging/methods , Prostatic Neoplasms/diagnostic imaging , Humans , Male , RadiopharmaceuticalsABSTRACT
INTRODUCTION: The global pandemic of COVID-19 has led to rapid implementation of telemedicine, but there is little information on patient satisfaction of this system as an alternative to face-to-face care. OBJECTIVE: To evaluate urological patient satisfaction with teleconsultation during the COVID-19 pandemic. MATERIAL AND METHODS: Observational, prospective, cross-sectional, non-interventional study carried out by telephone survey during the period considered as the peak of the pandemic (March-April 2020). A quality survey composed of 11 questions on urological care provided by physicians during the COVID-19 pandemic was conducted, selecting a representative sample of patients attended by teleconsultation. RESULTS: Two hundred patients were contacted by telephone to answer a survey on the quality of teleconsultation. The distribution of patients surveyed among the specialized consultations was homogeneous with the number of consultations cited in the period; 18% of them required assistance from family members. Sixty percent of patients avoided going to a medical center during the pandemic. Of the surveyed patients, 42% had cancelled diagnostic tests, 59% had cancelled medical consultations, 3.5% had cancelled treatments and 1% had cancelled interventions. Ten percent reported a worsening of urological symptoms during confinement. According to physicians, consultations were effectively delivered in 72% of cases, with teleconsultation being carried out by their usual urologist in 81%. Teleconsultation overall satisfaction level was 9 (IQI8-10), and 61.5% of respondents consider teleconsultation as a «health care option¼ after the healthcare crisis. CONCLUSION: Teleconsultation has been evaluated with a high level of satisfaction during the COVID-19 pandemic, offering continuous care to urological patients during the healthcare crisis. The perceived quality offers a field of optional telematic assistance in selected patients, which should be re-evaluated in a period without confinement measures.
Subject(s)
Betacoronavirus , Coronavirus Infections/epidemiology , Patient Satisfaction/statistics & numerical data , Pneumonia, Viral/epidemiology , Remote Consultation/statistics & numerical data , Urologic Diseases/psychology , Adult , Aged , Aged, 80 and over , Appointments and Schedules , COVID-19 , Cross-Sectional Studies , Disease Progression , Female , Humans , Male , Middle Aged , Pandemics , Prospective Studies , Quality of Health Care , SARS-CoV-2 , Surveys and Questionnaires , Young AdultABSTRACT
El cáncer de próstata (CP) es la segunda causa principal de mortalidad por cáncer y la enfermedad diagnosticada con mayor frecuencia en la población masculina. El CP se manifiesta de diversas maneras: desde enfermedad indolente a altamente agresiva. A esto se debe la complejidad de su diagnóstico y de la elección del tratamiento adecuado. El enfoque utilizado actualmente, con pruebas de PSA y examen rectal digital seguido de biopsia transrectal ecodirigida, carece de sensibilidad y especificidad en la detección de CP y ofrece información limitada sobre la agresividad y el estadio del cáncer. La evidencia científica respalda el creciente uso de la resonancia magnética multiparamétrica como la herramienta de imagen más sensible y específica para la detección, la caracterización de lesiones y la estadificación del CP. El presente estudio hace una revisión actualizada del rol de la resonancia magnética en el diagnóstico de CP, revisando los últimos artículos publicados en PubMed
Prostate cancer (PCa) is the second leading cause of cancer-related mortality and the most frequently diagnosed male malignant disease among men. The manifestation of PCa ranges from indolent to highly aggressive disease and due to this high variation in PCa progression, the diagnosis and subsequent treatment planning can be challenging. The current diagnostic approach with PSA testing and digital rectal examination followed by transrectal ultrasound biopsies lack in both sensitivity and specificity in PCa detection and offers limited information about the aggressiveness and stage of the cancer. Scientific work supports the rapidly growing use of multiparametric magnetic resonance imaging as the most sensitive and specific imaging tool for detection, lesion characterization and staging of PCa. Therefore, we carried out an updated review of magnetic resonance imaging in the diagnostic PCa reviewing the latest papers published in PubMed